Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | The need for alternative development pathways for CAR T-cell products

Andre Baruchel • 16 Feb 2024
CAR-T Meeting 2024
Acute Lymphoblastic Leukemia General Leukemia Rare Diseases CAR-T

In this video, André Baruchel, MD, PhD, Hospital Robert Debré AP-HP, Paris, France, discusses why alternative development pathways are needed for CAR T-cell products for the treatment of rare diseases in both the pediatric and adult setting. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andre Baruchel

The challenges with CAR T-cell therapy for T-ALL and the progress made to overcome these challenges
4:16
The challenges with CAR T-cell therapy for T-ALL and the progress made to overcome these challenges
Andre Baruchel • 16 Feb 2024
CAR-T therapy in ALL: exploring dual-targeting of CD19 & CD22 to overcome resistance
4:06
CAR-T therapy in ALL: exploring dual-targeting of CD19 & CD22 to overcome resistance
Andre Baruchel • 16 Feb 2024
Tisagenlecleucel in pediatric R/R B-cell ALL
7:41
Tisagenlecleucel in pediatric R/R B-cell ALL
Andre Baruchel • 28 Jun 2020
B-cell ALL with IGH-IL3 rearrangement and eosinophilia
7:17
B-cell ALL with IGH-IL3 rearrangement and eosinophilia
Andre Baruchel • 16 Jul 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals